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ABSTRACT    
 
Objective: Evidence on sex differences in outcomes after developing CHD 
has focused on recurrent CHD, all-cause mortality, or 
revascularisation. We assessed sex disparities in subsequent 
major adverse cardiovascular events (MACE) in adults surviving 
their first-time CHD. 
Methods: Using a population-based cohort obtained from the Clinical 
Practice Research Datalink (CPRD GOLD) linked to 
hospitalisation and death records in the UK, we identified 
143,702 adults (aged 18 years) between 1-1-1998 and 31-12-
2017 with no prior history of MACE. MACE outcome was a 
composite of recurrent CHD, stroke, peripheral vascular disease 
(PVD), heart failure, and cardiovascular-related mortality. 
Multivariable models (Cox and competing risks regressions) 
were used to assess differences between sexes.     
Results: There were 143,702 adults with any incident CHD (either 
angina, myocardial infarction, or coronary revascularisation). 
Women (n=63,078, 43.9%) were older than men (median age, 
73 vs 66 years). First subsequent MACE outcome was observed 
in 91,706 (63.8%). Women had a significantly lower risk for 
MACE [hazard ratio (HR), 0.68 (95% CI 0.67-0.69); sub-hazard 
ratio (HRsd), 0.71 (0.70-0.72), respectively] and recurrent CHD 
(n=66,543, 46.3%), [HR, 0.60 (0.59-0.61); HRsd, 0.62 (0.61-
0.63)] when compared with men after incident CHD. However, 
women had a significantly higher risk of stroke (n=5,740, 
4.0%), [HR, 1.26 (1.19-1.33); HRsd, 1.32 (1.25-1.39)], heart 
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failure (n=7,905, 5.5%), [HR, 1.09 (1.04-1.15); HRsd, 1.13 
(1.07-1.18)], and all-cause mortality (n=29,503, 20.5%), 
[HR,1.05 (1.02-1.07); HRsd, 1.11 (1.08-1.13)]. 
Conclusions: After incident CHD, women have lower risk of composite MACE 
and recurrent CHD outcomes but higher risk of stroke, heart 
failure and all-cause mortality compared with men. 
 
Keywords:  Coronary heart disease; major adverse cardiovascular events; 






RESEARCH IN CONTEXT 
What is already known about this subject? 
• Sex differences exist in the presentation, treatment, and outcomes in 
individuals with incident coronary heart disease (CHD). Most studies have 
focused on sex differences in recurrent CHD, all-cause mortality, or 
revascularisation.  
 
What does this study add? 
• Evidence on sex differences in first subsequent, composite major adverse 
cardiovascular events (MACE) and constituent outcomes in individuals with 
any incident CHD, using a large population-based cohort. 
 
How might this impact on clinical practice? 
• As more people are surviving their incident CHD events, further attention to 
all patients with incident CHD is needed to narrow this range of sex disparities 
in major subsequent clinical outcomes. Improving the standard and equity of 
care for women and men with incident CHD should recognise a ‘one size fits 






Coronary heart disease (CHD), is a global public health problem,[1] and remains a 
major cause of early morbidity and mortality despite advances in treatment and 
public health.[2] With many individuals surviving their initial CHD presentation, 
there is a growing population with established CHD with a substantially high risk of 
subsequent cardiovascular events or death.[3] The residual high risk in these 
individuals persists despite optimal therapy.[4] Greater and more nuanced 
understanding of their risk of subsequent events is needed to enable more targeted 
secondary prevention strategies. 
A large body of evidence has outlined differences in the clinical presentation,[5,6] 
diagnosis,[7] and management/treatment,[8–10] between men and women with an 
established diagnosis of CHD. Women with established CHD may have a lower 
probability of coronary revascularisation procedures[9] and a higher mortality 
outcome compared with men.[9] Most research examining sex differences in 
patients’ outcomes with CHD or CHD subtypes has focused primarily on recurrent 
CHD or CHD sub-types, all-cause mortality, revascularisation, or outcomes in the 
first year after CHD.[9,11] However there remains considerable uncertainty about 
wider experience of composite cardiovascular outcomes such as MACE (recurrent 
CHD, stroke, peripheral vascular disease, heart failure, and cardiovascular-related 
mortality) after incident CHD.   
In this population-based cohort study we used multiple databases of electronic 
health records from primary care consultations, secondary care (hospital admissions 
and procedure-level data), and the national death registry, to be representative of 
the UK population. We sought to estimate sex disparities in first subsequent MACE 





This prospective population-based cohort study used the UK CPRD GOLD database of 
anonymised longitudinal primary care electronic health records,[12] linked to 
secondary care hospitalisation data (Hospital Episode Statistics [HES]),[13] national 
mortality data (Office for National Statistics [ONS]),[14] and social deprivation data 
(Index of Multiple Deprivation (IMD) 2015).[15] Individuals included in the CPRD 
GOLD database, from a network of general practices across the UK, are 
representative of the UK general population in terms of sex, age, and ethnicity,[12] 
thereby validating CPRD GOLD for epidemiological research. This study was 
approved by the Independent Scientific Advisory Committee of the Medicines and 
Healthcare products Regulatory Agency (Protocol number 19_023R). 
 
Study population 
We identified a cohort of individuals with any incident non-fatal CHD in either 
primary care (CPRD GOLD) or secondary care (HES) data between 1 January 1998 
and 31 December 2017, so long as the patient has at least 12 months of registration 
at the practice, the diagnosis was made after the first 12 months of their current 
registration period[16], the practice was deemed to be contributing ‘up-to-standard’ 
data – Supplemental Methods, and the patient’s CPRD record had linkage to HES. 
CHD was defined as angina, myocardial infarction (MI), or coronary revascularisation 
(coronary bypass surgery or coronary angioplasty)[17] – Supplemental Table I for 
codes used in identifying both incident and outcome events. Individuals with a prior 
history of any stroke, peripheral vascular disease (PVD) or heart failure before 






First subsequent MACE after incident CHD was the primary outcome. MACE was 
defined as a composite of recurrent CHD, any stroke, PVD, heart failure, or 
cardiovascular-related mortality, based on record from across the linked data 
sources (CPRD, HES or ONS registry). All-cause mortality was considered as a 
secondary outcome.  
The study cohort and outcomes were identified from CPRD using Read codes, from 
HES using International Classification of Diseases, tenth revision (ICD-10) codes and 
Office of Population Censuses and Surveys Classification of Surgical Operations and 
Procedures (OPCS) revision 4.6 for procedure codes. All code lists used are available 
for download from https://portal.caliberresearch.org.[18]  
 
Cohort demographics and baseline characteristics 
Age was defined at the time of incident CHD. Ethnicity was categorised into six 
groups: Asian, Black, Mixed, Other, White, and unknown.[19] To describe 
socioeconomic status, the English Index of Multiple Deprivation 2015[15] linked to 
the individual’s residential postcode was used. IMD is a weighted mean across the 
seven domains, hence offers a single score to describe the concept of deprivation; 
categorised into quintiles (quintile 1 – least deprived group to quintile 5 – most 
deprived group). Medication prescriptions (issue of prescription) at baseline was 
defined as a prescription within 12 months before incident CHD. For cholesterol (low 
density lipoprotein (LDL), high density lipoprotein (HDL) and total), body mass index 
(BMI), and blood pressure measures (diastolic and systolic), the most recent 
values/measures within 24 months before incident CHD were used. All other 





The Shapiro-Wilk Test was used to assess normality of distribution for continuous 
variables. Mann-Whitney U test for continuous data and chi-squared test for 
categorical data were used to compare baseline characteristics between men and 
women. The level of missing values ranged between 17.5% for blood pressure 
measures to 62.7% for LDL-C. Details on the proportion of missingness and 
differences in characteristics between those with and without missing data are 
provided in the Supplemental Tables II and III. To estimate missing values for BMI, 
systolic and diastolic blood pressures, HDL-C, LDL-C and total cholesterol levels, 
multiple imputation by chained equations was used to generate 10 imputed datasets 
using all the other available patient variables, and all the outcomes.[20] The 
imputed datasets were pooled into a single dataset using Rubin’s rules.[21] Age-
standardised prevalence for comorbidities and prescribed medications at baseline 
were obtained by using the study population to standardise the prevalence across 
men and women. 
Incidence rates with 95% confidence intervals (CI) for first subsequent MACE, its 
individual constituents, and all-cause mortality end points were calculated by 
dividing the number of incident outcomes by the total person-years at risk. Kaplan-
Meier curves accompanied by hazard ratios from Cox proportional hazard regression 
models were used to analyse the time-to-event outcomes. Competing-risk analysis, 
which provides the cause-specific (or sub-) hazard ratio, was used to calculate the 
cumulative incidence of the outcomes. The method proposed by Fine and Gray[22] 
was used to estimate association of sex with the sub-hazard of MACE (or the specific 
individual constituent of MACE) and all-cause mortality. Non-cardiovascular-related 
mortality was considered a competing risk for MACE outcome. For both Cox and 
competing risks models, results are presented for models adjusted for age (Model 1) 
and models adjusted for age, socioeconomic status (SES), smoking status, BMI, 
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blood pressure (diastolic and systolic), total cholesterol level, history of alcohol 
problem, diabetes mellitus (DM), dyslipidaemia, cancer, chronic kidney disease 
(CKD), hypertension, atrial fibrillation (AF), depression and a family history of 
cardiovascular disease (Model 2). The composite MACE outcome was further 
analysed using a win-ratio approach,[23] first described by Finkelstein and 
Schoenfeld,[24] which prioritizes fatal outcome(s) (that is, cardiovascular-related 
death) over less severe or non-fatal outcomes (that is, recurrent CHD, stroke, PVD, 
and heart failure) for composite outcome. The R package, WWR, was used for the 
Win Ratio analysis. In a sensitivity analysis, subsequent outcomes within 30 days 
were considered as representing or relating to the same incident CHD event.[25]  
Analyses were, therefore, restricted to subsequent outcomes occurring after 30 days 
of incident CHD. All statistical analyses were performed using Stata SE version 16.1 
(StataCorp LP) and R version 4.0.3. An alpha level of 0.05 was used for all analyses. 
Patient and public involvement 
Patients or the public were not involved in the design, conduct, or reporting. We plan 




There was a total of 166,068 individuals aged 18 years and over with any incident 
CHD between 1998 and 2017 in either CPRD GOLD or HES. 22,366 of these 
individuals with a record of a major adverse event prior to their incident CHD event 
were excluded from the analysis. The study, therefore, included a cohort of 143,702 




The median follow-up time was 13.4 years (interquartile range (IQR): 8.4-17.7 
years). The cohort comprised 63,078 (43.9%) women and were older than the men 
(median age of 73 vs 66 years, p≤0.001). Detailed descriptive characteristics for the 
study cohort presented by sex are presented in Table 1.   
After adjustment for age, women had a higher prevalence of the following 
comorbidities and known risk factors at time of incident CHD when compared to 
men: chronic kidney disease (9.3% vs 8.2%), depression (25.6% vs 13.0%), 
dyslipidaemia (12.9% vs 11.2%), family history of CVD (27.7% vs 21.0%), 
hypertension (46.9% vs 40.6%), hypothyroidism (10.9% vs 2.8%), migraine (9.1% 
vs 3.2%), and rheumatoid arthritis (2.5% vs 1.2%). Within 12 months prior to 
incident CHD, women had a higher number of prescriptions for anti-arrhythmic, anti-
depressant, anti-epileptic, anti-hypertensive, anti-platelet, beta-blockers, 
corticosteroid, diuretics, and both low- and high-intensity statins, after adjusting for 
age. Supplemental Table IV details the age-adjusted prevalence for comorbidities, 
risk factors, and prescribed medications. 
 
First subsequent MACE outcome 
Most first subsequent major adverse outcomes occurred within 2 years of incident 
CHD, with median time to outcome ranging from 0.11 years (IQR: 0.02-0.81) for 
recurrent CHD to 2.54 years (IQR: 0.63-5.83) for subsequent stroke event. Of the 
143,702 individuals with incident CHD, 91,706 (63.8%) had a MACE [men: 55,087 
(68.3%) vs women: 36,619 (58.1%)]; 66,543 (46.3%) had a recurrent CHD; 5,740 
(4.0%) strokes; 1,624 (1.1%) PVD; 7,905 (5.5%) heart failure; 9,894 (6.9%) 
cardiovascular death; and 29,503 (20.5%) all-cause death, occurring after the 
incident CHD events. Figure 2 and Supplemental Figure II show the distribution of 
individuals with major adverse outcomes, by sex and across 5-year age bands.  
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Incidence rate for clinical outcomes 
The overall incidence rate for MACE was 25.18 per 100 person-years (95% CI: 
25.02–25.34), with a higher incidence rate in men compared to women (31.03 vs 
19.62 per 100 person-years). Table 2 details the sex variation in the incidence of the 
constituent MACE outcomes. In comparing women to men, the age- and SES-
adjusted sex-specific IRR for MACE was 0.58 (0.57–0.59), for recurrent CHD 0.52 
(0.51–0.53), stroke: 1.22 (1.16–1.29), PVD: 0.88 (0.80–0.97), heart failure: 1.00 
(0.96–1.05), CVD-related death: 0.89 (0.85–0.93), and all-cause mortality: 0.92 
(0.90–0.94). 
Sex difference and clinical outcomes 
After adjusting for age, socioeconomic and smoking status, BMI, blood pressure, 
total cholesterol, history of alcohol problem, diabetes, dyslipidaemia, cancer, CKD, 
hypertension, AF, depression, and family history of CVD, in both Cox and competing 
risks models (Table 3) women had a significantly lower risk of first subsequent MACE 
[hazard ratio (HR), 0.68 (95% CI 0.67-0.69); sub-hazard ratio (HRsd), 0.71 (95% 
CI 0.70-0.72), respectively] and recurrent CHD [HR, 0.60 (95% CI 0.59-0.61); 
HRsd, 0.62 (95% CI 0.61-0.63)] when compared with men after incident CHD. 
Women, however, had a significantly higher risk of any stroke [HR, 1.26 (95% CI 
1.19-1.33); HRsd, 1.32 (95% CI 1.25-1.39)], heart failure [HR, 1.09 (95% CI 1.04-
1.15); HRsd, 1.13 (95% CI 1.07-1.18)], and all-cause mortality [HR,1.05 (95% CI 
1.02-1.07); HRsd, 1.11 (95% CI 1.08-1.13)].  
The cumulative incidence function (CIF) [Figure 2 and Supplemental Figure III] and 
Kaplan-Meier curves (Figure 3 and Supplemental Figure IV) as well as the adjusted 
Kaplan-Meier cumulative incidence curves (Supplemental Figure V) for MACE and its 
constituent outcomes illustrate women have a higher incidence of subsequent 
stroke, heart failure, and all-cause mortality over a 10-year follow-up period.      
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To describe the effect of being a woman on the fatal outcome (cardiovascular-
related death) in the composite MACE as compared to the non-fatal outcomes 
(recurrent CHD, stroke, PVD, and heart failure), the win ratio was 1.331 (95% CI 
1.329-1.331). 
Sensitivity analysis 
For the sensitivity analysis, 7,566 (5.3%) individuals who died within 30 days of 
incident CHD were excluded. There were 76,571 subsequent MACE outcomes 
recorded after 30 days of incident CHD for the remaining 136,326 individuals. The 
median time from incident CHD to subsequent outcome after 30 days ranged from 
0.58 years (IQR: 0.21-2.25) for recurrent CHD to 2.98 years (IQR: 0.85-6.59) for 
all-cause mortality, Supplemental Table V. After full adjustment, in both Cox and 
competing risks models (Supplemental Table VI) women had a significantly lower 
risk of first subsequent MACE [HR, 0.70 (95% CI 0.69-0.71); sub-hazard ratio 
(HRsd), 0.71 (95% CI 0.70-0.72), respectively] and recurrent CHD [HR, 0.63 (95% 
CI 0.62-0.64); HRsd, 0.64 (95% CI 0.63-0.65)] when compared with men after 
incident CHD. Women, however, had a significantly higher risk of any stroke [HR, 
1.21 (95% CI 1.15-1.28); HRsd, 1.27 (95% CI 1.20-1.34)] and all-cause mortality 
[HR,1.01 (95% CI 0.98-1.04); HRsd, 1.08 (95% CI 1.05-1.11)]. Similar sex 
differences were observed when the analysis was done by incident CHD time period 
(1998-2007 and 2008-2017) – Supplemental Table VII and when the analysis was 







Within a population-based cohort, we show there are sex disparities in the risk of 
developing first subsequent major adverse cardiovascular event (MACE) and its 
individual constituent events in adults with any incident CHD. Women are less likely 
to have a MACE or recurrent CHD as a first subsequent event after incident CHD 
when compared to men. However, women are more likely to have stroke, heart 
failure, or death from any cause after incident CHD.  
 
The risk profiles of men and women have been shown to substantially differ when 
diagnosed with CHD[26] and fare much differently after incident CHD. The cause of 
disparities are multifaceted, relating to differences in baseline cardiovascular profile, 
access to care, use of resources and evidence-based guidelines, social as well as 
environmental factors.[8,27] Previous studies have frequently been based on 
selected cohorts from trials, registries or individuals with specific type of CHD.[9,26] 
Consistent with our findings, a study of 3,779 patients from the Euro Heart Survey 
of Stable Angina reported women have a higher risk of death even after 
multivariable adjustment.[9] However, in a study of 30,977 outpatients with stable 
coronary artery disease from the CLARIFY register, similar event rates in men and 
women for the composite outcome of cardiovascular death, non-fatal MI or stroke at 
1-year follow-up was observed after adjustment for baseline differences.[26] 
Although 22.6% of the CLARIFY study patients were women, women were more 
likely to have diabetes and hypertension – consistent with our findings. 
Population-based studies, such as our study using data representative of the UK 
population, provide real-world evidence regarding sex differences in outcomes for 
patients with incident CHD.[28] It is by considering disparities across individuals 
from the whole spectrum of CHD that the full burden of subsequent MACE outcome 
can be captured, and accurate distinctions made between men and women. Most 
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studies have focused on sex differences in mortality outcome – differences in age, 
comorbidities, and treatment use between men and women have largely explained 
the sex differences in mortality outcome.[11] Studies have also differed in the 
methodological approach used in assessing sex differences – logistic regression[26] 
as opposed to survival analysis.  
The analysis of survival (time-to-event) data plays a key role in cardiovascular 
research and competing events are prevalent.[29] A competing event (e.g., death 
from non-cardiovascular cause) hinders or changes the possibility of observing the 
outcome of interest (e.g., death from cardiovascular-related death). Koller et al, 
found a large majority of clinical studies neglected the competing risks process 
despite the studies having populations susceptible to competing risks.[29] Failure to 
account correctly for these competing events results in the overestimation of 
probabilities for the incidence of outcomes.[30] Our analyses illustrated the 
overestimation of the risk of first subsequent MACE and its constituents when using 
a standard Cox model. Our study demonstrates the importance of accounting for 
competing events. The impact of incorrectly treating competing events has practical 
importance as clinical decisions often rely on an individual’s risk of a disease event 
or outcome.[31]  
Combining multiple types of clinical outcomes into a single composite outcome is 
common in clinical research.[32] The usual analysis of time to first occurrence of any 
event in the composite outcome treats individual constituent outcomes as being 
equally important despite differences in clinical relevance and severity. The novel 
approach, win ratio,[23] provides a useful alternative for analyses of composite 
outcomes, addressing the limitations of usual first event analysis. Win ratio requires 
a ranking of outcomes by severity but does not require assigning a specific weight to 
each outcome. As shown in our study, women have more fatal outcome in composite 




Strengths and limitations 
This study has a number of strengths. First, the size and representativeness of the 
CPRD GOLD dataset[12] – this large retrospective population-based study used 
primary care data linked to hospital and mortality records allowing us to assess sex-
related differences in major CVD events and mortality occurrence after incident 
CHD. Second, we used an incident cohort, which reflects current practice and avoids 
the distorting influences of bias present in cohorts with prevalent major adverse 
events. We acknowledge limitations generally inherent in studies using electronic 
health records (EHRs). These including missing data in EHRs including CPRD GOLD. 
Potential ascertainment and information bias are acknowledged. The coded 
definitions of outcomes and CHD incident diagnosis used in this study are, however, 
well-established due to the pay-for-performance scheme (Quality and Outcome 
Framework) which has improved documentation/coding for cardiovascular conditions 
and associated risk factors.[17,33] The potential for misclassification bias is, 
therefore, not likely. The sub-typing of CHD in both primary care (CPRD GOLD) and 
secondary care (HES) databases are not reliable;[34] hence unable to assess 
differences for CHD sub-types. The use of ‘softer’ CHD codes in primary care data is 
yet to be validated.[35]         
 
Conclusions 
Coronary heart disease remains the leading cause of mortality globally. Improved 
understanding of outcomes in patients with CHD is key to reduce the disease 
burden. In this large population-based cohort study of patients with any type of 
incident CHD, we identified after appropriate adjustments for confounders, a lower 
risk of MACE and recurrent CHD for women when compared with men. However, 
there was a higher risk for stroke, heart failure, and all-cause mortality in women. 
As more people are surviving their incident CHD events, further attention to all 
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patients with incident CHD is needed to narrow this range of sex disparities in major 
subsequent clinical outcomes. Improving the standard and equity of care for women 
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p-value 143,702 (100) 80,624 (56.1) 63,078 (43.9) 
Follow-up (years), median (IQR) 13.4 (8.4 – 17.4) 13.5 (8.7 – 17.5) 13.0 (8.1 – 17.2)  
Age (years) 69 (59 – 78) 66 (56 – 75) 73 (63 – 81) 0.0001 
Ethnicity    <0.001 
Asian 3,550 (2.5) 2,202 (2.7) 1,348 (2.1)  
Black 959 (0.7) 504 (0.6) 455 (0.7)  
Mixed 361 (0.3) 209 (0.3) 152 (0.2)  
Other 1,174 (0.8) 727 (0.9) 447 (0.7)  
White 130,236 (90.6) 72,844 (90.4) 57,392 (91.0)  
Unknown 7,422 (5.2) 4,138 (5.1) 3,284 (5.2)  
Socioeconomic status    <0.001 
1 (Least deprived) 30,273 (21.1) 17,962 (22.3) 12,311 (19.5)  
2 31,412 (21.9) 17,963 (22.3) 13,449 (21.3)  
3 30,259 (21.1) 16,963 (21.0) 13,296 (21.1)  
4 26,808 (18.7) 14,507 (18.0) 12,301 (19.5)  
5 (Most deprived) 24,754 (17.2) 13,122 (16.3) 11,632 (18.4)  
Unknown 196 (0.1) 107 (0.1) 89 (0.1)  
Current smokers 27,750 (19.3) 17,664 (21.9) 10,086 (16.0) <0.001 
Alcohol problem 3,456 (2.4) 2,600 (3.2) 856 (1.4) <0.001 
Body mass index (kg/m2) 27.7 (25.8 – 30.1) 27.9 (26.0 – 30.1) 27.6 (25.5 – 30.0) 0.0001 
Diastolic blood pressure (mmHg) 80 (74 – 85) 80 (75 – 85) 80 (72 – 84) 0.0001 
Systolic blood pressure (mmHg) 140 (130 – 149) 140 (130 – 148) 140 (130 – 150) 0.0001 
HDL cholesterol (mmol/L) 1.4 (1.2 – 1.6) 1.3 (1.1 – 1.5) 1.5 (1.3 – 1.7) 0.0001 
LDL cholesterol (mmol/L) 3.1 (2.6 – 3.5) 3.1 (2.6 – 3.5) 3.1 (2.6 – 3.6) 0.0001 
Total cholesterol (mmol/L) 5.2 (4.7 – 5.7) 5.1 (4.6 – 5.6) 5.3 (4.8 – 5.8) 0.0001 
Comorbidities 
Atrial fibrillation 11,286 (7.9) 6,022 (7.5) 5,264 (8.4) <0.001 
Cancer 18,311 (12.7) 9,954 (12.4) 8,357 (13.3) <0.001 
Chronic kidney disease 12,344 (8.6) 5,545 (6.9) 6,799 (10.8) <0.001 
COPD 9,442 (6.6) 5,302 (6.6) 4,140 (6.6) 0.922 
Depression 25,967 (18.1) 11,045 (13.7) 14,922 (23.7) <0.001 
Diabetes mellitus 19,861 (13.8) 11,403 (14.1) 8,458 (13.4) <0.001 
Type-1 diabetes 1,615 (1.1) 898 (1.1) 717 (1.1) 0.683 
Type-2 diabetes 16,238 (11.3) 9,408 (11.7) 6,830 (10.8) <0.001 
Dyslipidaemia 17,303 (12.0) 9,336 (11.6) 7,967 (12.6) <0.001 
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Family history of coronary heart 
disease 
26,528 (18.5) 14,017 (17.4) 12,511 (19.8) <0.001 
Family history of cardiovascular 
disease 
34,213 (23.8) 17,952 (22.3) 16,261 (25.8) <0.001 
Hypertension 62,493 (43.5) 31,536 (39.1) 30,957 (49.1) <0.001 
Hypothyroidism 9,154 (6.4) 2,102 (2.6) 7,052 (11.2) <0.001 
Lupus erythematosus 324 (0.2) 77 (0.1) 247 (0.4) <0.001 
Migraine 7,797 (5.4) 2,776 (3.4) 5,021 (8.0) <0.001 
Moderate-severe liver disease  452 (0.3) 250 (0.3) 202 (0.3)  0.733 
Rheumatoid arthritis 2,576 (1.8) 963 (1.2) 1,613 (2.6) <0.001 
Severe mental illness 1,371 (1.0) 658 (0.8) 713 (1.1) <0.001 
Transient ischaemic attack 5,159 (3.6) 2,534 (3.1) 2,625 (4.2) <0.001 
Drug prescription 
Anti-arrhythmic 7,346 (5.1) 3,348 (4.2) 3,998 (6.3) <0.001 
Anti-coagulant 8,429 (5.9) 4,569 (5.7) 3,860 (6.1) <0.001 
Anti-depressant 30,139 (21.0) 12,245 (15.2) 17,894 (28.4) <0.001 
Anti-diabetic 16,170 (11.3) 9,271 (11.5) 6,899 (10.9) 0.001 
Anti-epileptic 9,746 (6.8) 4,612 (5.7) 5,134 (8.1) <0.001 
Anti-hypertensive 77,180 (53.7) 39,738 (49.3) 37,442 (59.4) <0.001 
Antiplatelets 47,799 (33.3) 25,365 (31.5) 22,434 (35.6) <0.001 
Beta-blockers 39,692 (27.6) 20,103 (24.9) 19,589 (31.1) <0.001 
Corticosteroid 16,541 (11.5) 7,560 (9.4) 8,981 (14.2) <0.001 
Diuretics 47,885 (33.3) 20,069 (24.9) 27,816 (44.1) <0.001 
Statin    <0.001 
Low intensity 5,810 (4.0) 2,978 (3.7) 2,832 (4.5)  
Moderate intensity 29,331 (20.4) 16,946 (21.0) 12,385 (19.6)  




1,969 (1.4) 1,488 (1.9) 481 (0.8) <0.001 
CHD: coronary heart disease; n: total number; %: percentage/proportion; COPD: chronic obstructive 
pulmonary disease; HDL: high density lipoprotein; LDL: low density lipoprotein; MACE: major adverse 





Table 2. Incidence of first subsequent major adverse outcomes (n = 143,702)   
  





Incidence rate  
(per 100 person-years)  
Adjusted incidence 
rate ratio † 
MACE (All) 0.18 (0.03 – 1.59) 91,706 3,600 25.18 (25.02 – 25.34)  
Men 0.13 (0.02 – 1.04) 55,087 1,800 31.03 (30.77 – 31.29) Reference 
Women 0.31 (0.04 – 2.47) 36,619 1,900 19.62 (19.42 – 19.82) 0.58 (0.57 – 0.59) 
Coronary heart disease (All) 0.11 (0.02 – 0.81) 66,543 3,900 16.87 (16.74 – 17.00)  
Men 0.09 (0.02 – 0.58) 43,238 1,900 22.29 (22.08 – 22.50) Reference 
Women 0.17 (0.03 – 1.29) 23,305 2,000 11.63 (11.48 -11.78) 0.52 (0.51 – 0.53) 
Stroke (All) 2.54 (0.63 – 5.83) 5,740 7,500 0.77 (0.75 – 0.79)  
Men 2.33 (0.52 – 5.56) 2,546 4,300 0.60 (0.57 – 0.61) Reference 
Women 2.75 (0.71 – 6.07) 3,194 3,200 1.00 (0.97 – 1.04) 1.22 (1.16 – 1.29) 
Peripheral arterial disease (All) 1.83 (0.35 – 4.88) 1,624 7,500 0.22 (0.21 – 0.23)  
Men 1.71 (0.35 – 4.68) 901 4,300 0.21 (0.19 – 0.22) Reference 
Women 1.95 (0.34 – 5.20) 723 3,200 0.23 (0.21 – 0.24) 0.88 (0.80 – 0.97) 
Heart failure (All) 0.95 (0.14 – 3.83) 7,905 7,400 1.07 (1.05 – 1.09)  
Men 0.73 (0.11 – 3.54) 3,823 4,300 0.90 (0.87 – 0.93) Reference 
Women 1.22 (0.19 – 4.11) 4,082 3,100 1.30 (1.26 – 1.34) 1.00 (0.96 – 1.05) 
Cardiovascular mortality (All) 0.20 (0.02 – 3.13) 9,894 7,600 1,29 (1.27 – 1.32)  
Men 0.21 (0.-2 – 3.06) 4,579  4,400 1.04 (1.02 – 1.08) Reference 
Women 0.19 (0.02 – 3.22) 5,315 3,300 1.63 (1.59 – 1.67) 0.89 (0.85 – 0.93) 
All-cause mortality (All) 1.37 (0.08 – 5.07) 29,503 7,800 3.77 (3.73 – 3.82)  
Men 1.20 (0.07 – 4.78) 13,668 4,500 3.07 (3.02 – 3.12) Reference 
Women 1.54 (0.08 – 5.34) 15,835 3,400 4.71 (4.63 – 4.78) 0.92 (0.90 – 0.94) 
 
* 100 person-years at risk; All – both men and women; Follow-up time: median follow-up time in years reported with interquartile range. 
† Incident rate ratio adjusted for age (continuous variable) and index of multiple deprivation (socioeconomic status). 
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Table 3. Risk of first subsequent major adverse outcome for women 
compared to men (reference category) 
 Cox model 
Hazard ratio (95% CI) 
Competing risks model * 
Sub-hazard ratio (95% CI) 
Model 1 † 
Major adverse cardiovascular event 0.68 (0.67 – 0.69) 0.71 (0.70 – 0.72) 
Coronary heart disease 0.62 (0.61 – 0.63) 0.64 (0.63 – 0.65) 
Stroke 1.25 (1.18 – 1.32) 1.33 (1.26 – 1.41) 
Peripheral vascular disease 0.92 (0.83 – 1.02) 0.95 (0.86 – 1.06) 
Heart failure 1.04 (1.00 – 1.09) 1.09 (1.04 – 1.14) 
Cardiovascular-related death 0.94 (0.90 – 0.98) 0.99 (0.95 – 1.03) 
All-cause mortality 0.96 (0.94 – 0.98) 1.02 (1.00 – 1.05) 
Model 2 ‡ 
Major adverse cardiovascular event 0.67 (0.66 – 0.68) 0.69 (0.68 – 0.70) 
Coronary heart disease 0.60 (0.59 – 0.61) 0.62 (0.61 – 0.63) 
Stroke 1.26 (1.19 – 1.33) 1.32 (1.25 – 1.39) 
Peripheral vascular disease 0.92 (0.83 – 1.02) 0.95 (0.85 – 1.05) 
Heart failure 1.09 (1.04 – 1.15) 1.13 (1.07 – 1.18) 
Cardiovascular-related death 0.99 (0.95 – 1.03) 1.02 (0.98 – 1.06) 
All-cause mortality 1.05 (1.02 – 1.07) 1.11 (1.08 – 1.13) 
 
* Fine and Gray method for sub-distribution regression with competing risks[22] 
† Model 1 – adjusted for age (continuous variable) 
‡ Model 2 – adjusted for age, (continuous variable), socioeconomic status, smoking status, body 
mass index, blood pressure, total cholesterol level, history of alcohol problem, diabetes mellitus, 
dyslipidaemia, cancer, chronic kidney disease, hypertension, atrial fibrillation, depression, and a 








Figure 1. Distribution of first subsequent major adverse outcomes by sex 
and 5-year age group for patients with incident CHD 
 
Figure 2. Cumulative incidence function plots for first subsequent major 
adverse outcomes 
 
Figure 3. Kaplan-Meier plots for first subsequent major adverse 
outcomes 
 
